ArticleJournal of medical toxicology : official journal of the American College of Medical Toxicology2026
The Toxicology Investigators Consortium 2024 Annual Report.
Article in Journal of medical toxicology : official journal of the American College of Medical Toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dexmedetomidine in The Treatment of Toxicologic Conditions in The Emergency Department: A Dual-Center Retrospective Observational Cohort Study.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Established in 2010, the American College of Medical Toxicology (ACMT) Toxicology Investigators Consortium (ToxIC) Core Registry has systematically captured data from in-hospital and clinic-based medical toxicology physician consultations across the United States (US) and internationally. The ToxIC Core Registry contains deidentified patient data, including patient demographics, reason for medical toxicology evaluation, exposure agents, clinical signs and symptoms, treatments and antidotes administered, and mortality outcomes. This fifteenth annual report provides data from 8,868 patients entered into the Core Registry in 2024, bringing the total number of cases to 111,276 between 2010 and 2024. These cases were submitted by 41 participating sites encompassing 67 distinct hospitals over 23 US states and 3 international countries. In 2024, ethanol was the most commonly reported exposure agent class (17.8%), followed by opioids (15.8%), non-opioid analgesics (10.5%), and sympathomimetic agents (7.6%). A total of 107 fatalities were reported, corresponding to a case fatality rate of 1.2%. Additional descriptive analyses in this annual report were conducted to describe trends for opioid and psychoactive exposures between 2010 and 2024.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.